STAT editors and reporters review the widespread impact of grant cuts, layoffs and policy changes — and also discuss recent ...

Eli Lilly (LLY) is among the list of large-cap pharmaceutical companies that are awaiting the Trump administration's word on ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Eli Lilly CEO Dave Ricks took a stand against Trump's tariffs in a Q1 earnings call. The medicine company has strong operations for obesity and weight loss drugs in Ireland.

US drug prices are up to five times higher than in other developed nations. Trump's order requires US drug prices to align ...

Big move on Thursday as investors in Eli Lilly and ... seen whether the Trump administration might institute measures to lower the pricing power of NVO and LLY just when Lilly has the potential ...

The U.S. Food and Drug Administration has cleared Fujirebio Diagnostics' blood test to diagnose Alzheimer's disease, the regulator said on Friday, making the device the first of its kind to detect ...

The market uncertainty brought on essentially by the tariff changes that can impact ... a time when the Trump administration is pushing for more manufacturing in the U.S., Eli Lilly then looks ...

The head of drugmaker Eli Lilly, which sells the popular weight-loss drug Zepbound, urged the Trump administration to ease up on its tariff rollout because it could hurt Lilly’s business and the ...

President Trump recently warned big drugmakers that ... the president warned that a "tariff wall" is coming. Although AbbVie, Eli Lilly, and Johnson & Johnson manufacture many of their products ...

Johnson & Johnson factored roughly $400 million into its 2025 guidance to account for the impact ... the Trump administration could unleash an even bigger threat than tariffs to AbbVie, Lilly ...